AlzeCure Pharma AB, a developer of drugs for diseases affecting the central nervous system focusing on Alzheimer's disease and pain, has appointed Cecilia Wadell as head of development as the Swedish company brings candidates to clinical development. Dr Wadell has more than 25 years of pharmaceutical industry experience, leading clinical development projects, including for orphan drugs, and building R&D organisations. She has held senior positions at both major and smaller companies including AstraZeneca, Wilson Therapeutics and Medivir.
Copyright 2025 Evernow Publishing Ltd